Earnings Summary

Merrimack Pharmaceuticals, Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q3 2023. On a quarterly growth basis, Merrimack Pharmaceuticals, Inc has generated NaN% jump in its revenue since last 3-months.

Merrimack Pharmaceuticals, Inc’s net profit jumped 12.26% since last year same period to $-0.28Mn in the Q3 2023. On a quarterly growth basis, Merrimack Pharmaceuticals, Inc has generated 28.64% jump in its net profits since last 3-months.

Merrimack Pharmaceuticals, Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q3 2023. On a quarterly growth basis, Merrimack Pharmaceuticals, Inc has generated NaN% jump in its net profit margins since last 3-months.

Merrimack Pharmaceuticals, Inc’s earning per share (EPS) estimates for the current quarter stand at -1 - a -20.48% fall from last quarter’s estimates.

Merrimack Pharmaceuticals, Inc’s earning per share (EPS) estimates for the current year stand at -1.

Merrimack Pharmaceuticals, Inc’s earning per share (EPS) jumped 40.91% since last year same period to -0.02 in the Q3 2023. This indicates that the Merrimack Pharmaceuticals, Inc has generated 40.91% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Merrimack Pharmaceuticals, Inc’s return on assets (ROA) stands at -0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Merrimack Pharmaceuticals, Inc’s return on equity (ROE) stands at -0.09.